Gundesen MT, Schjesvold F, Lund T(2025) Treatment of myeloma bone disease: When, how often, and for how long? J Bone Oncol, 52, 100680 DOI 10.1016/j.jbo.2025.100680, PubMed 40242221
Richter J, Nooka A, Rodríguez-Otero P, Schjesvold F, Katodritou E, Combe E, Scott M, Cooper L, Sly I, Ballew N, Bitetti J, Boytsov N, Purser M, McNamara S(2025) Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis Am J Hematol(in press) DOI 10.1002/ajh.27661, PubMed 40143674
Askeland FB, Haukås E, Slørdahl TS, Klostergaard A, Alexandersen T, Lysén A, Abdollahi P, Nielsen LK, Hermansen E, Schjesvold F(2025) Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial Lancet Haematol, 12(2), e120-e127 DOI 10.1016/S2352-3026(24)00347-8, PubMed 39909655